New schizophrenia drug shows promise in reducing symptoms
NCT ID NCT07550387
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new medication called HS-10380 in 363 Chinese adults hospitalized with acute schizophrenia. The goal was to see if it reduces symptoms like hallucinations and delusions better than a placebo or an existing drug. Participants took the drug for 6 weeks, and doctors measured changes using a standard symptom scale.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, 200030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill for schizophrenia pass its first human test?
- Can a new daily pill offer safer Long-Term control of schizophrenia?
- Can an Anti-Seizure drug quiet the brain and sharpen thinking in schizophrenia?
- Role-Play with a simulated patient: a new way to train nurses in mental health?
- Can a dissolving film tame agitation in schizophrenia?
- Can a phone app teach the brain to read social cues?